Equity
-€33,296
Debts exceed assets in financial year 2025.
PHARMA PROJECT
Lifetime
19 annual accounts with figures on one time axis, 29 filings since 1997peak €352,016 (2018)
€83,959▼ 14.6%
lowest -€109,042 (2016)
-€11,278▼ €12,905
peak €467,932 (2008)
-€33,296▼ €11,278
€839,308▼ 5.2%
Board4 names since 2020
2 directors and 1 other
Documentsfilings and deeds
05-01-202626 days before the deadline
2025micro format
Gross margin from €98,259 to €83,959Loss of €11,278Equity from -€22,018 to -€33,296
Key points
from the 2025 annual accountsChecked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 1,240 companies had the same profile as PHARMA PROJECT has now. Each dot stands for 4 companies, two years later.
92.7%
were still trading
4.0%
stopped another way
1.9%
went bankrupt
Another 1.4% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,331 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 1,240 companies, not a prediction for PHARMA PROJECT. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0458257001
1 director appointed, 2 resignations
Resignations: and · Appointment: (sole director) · Director discharge: · General meeting of 30-11-2023 · Gazette deed
3 directors reappointed
(managing director), and · General meeting of 14-11-2020 · Gazette deed
First establishment
Place Cardinal Mercier 6, Wavre
Official details
Source: KBO- Status
- Active since 19-06-1996Normal situation
- Activity
- “Acheter,échanger ou vendre publiquement ou de gré à gré,des immeubles bâtis ou non bâtis,ainsi…” (deed in French)From the articles, 6 activitiesNo NACE code in the KBO yet
- Establishment unit
- 2.079.468.9741300 Wavre, since 12-12-1996
- Financial year end
- 30 June
- Peppol
- Reachable since 04-05-2026
Annual accounts to 30-06-2025
- €806,013▼ 6.6%
- Filing
- Filed on 05-01-2026, 26 days before the end of the filing period
Insights on PHARMA PROJECT
PHARMA PROJECT files the micro format. That format states no turnover. The gross margin fell from €95,981 in 2007 to €83,959 in 2025.
The balance sheet grew most from 2008 to 2010 through fixed assets.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about PHARMA PROJECT
- What is the company number of PHARMA PROJECT?
- The company number of PHARMA PROJECT is 0458.257.001. The VAT number is the same number with BE in front: BE 0458.257.001.
- Where is PHARMA PROJECT based?
- The registered office is at Place Cardinal Mercier 6, 1300 Wavre.Company details
- What is the legal form of PHARMA PROJECT?
- PHARMA PROJECT is a public limited company (NV).
- When was PHARMA PROJECT founded?
- PHARMA PROJECT was founded on 19-06-1996.
- Is PHARMA PROJECT still active?
- Yes, PHARMA PROJECT is an active enterprise in the KBO register.
- What is the turnover of PHARMA PROJECT?
- The turnover in financial year 2025 is ≈ €250,000. This figure is estimated from the gross margin of €83,959 and 2,666 comparable companies of the same size. It probably lies between €170,000 and €440,000. It is a rough estimate.Financials
- Is PHARMA PROJECT profitable?
- In financial year 2025, PHARMA PROJECT made a loss of €11,278.
- Where can I find the annual accounts of PHARMA PROJECT?
- PHARMA PROJECT filed 29 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of PHARMA PROJECT due?
- PHARMA PROJECT must file the annual accounts for financial year 2026 by 31-01-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.